Core Viewpoint - RemeGen has entered a licensing agreement with AbbVie for RC148, which includes significant upfront and milestone payments, indicating strong market expectations for the drug's potential [1] Company Summary - RemeGen will receive an upfront payment of US$650 million and milestone payments of up to US$4.95 billion from AbbVie for the rights to develop, manufacture, and commercialize RC148 outside Greater China [1] - The licensing agreement is expected to alleviate RemeGen's cash position, which was RMB1.45 billion as of September 30, 2025 [2] Clinical Data Summary - RC148 demonstrated an overall response rate (ORR) of 61.9% and a disease control rate (DCR) of 100% in first-line PD-L1-positive NSCLC patients [2] - In combination with docetaxel for second/third-line NSCLC, RC148 showed an ORR of 66.7% and a median progression-free survival (mPFS) of 8.3 months [2] - The safety profile of RC148 is considered manageable, with clinical benefits observed across all subgroups [2] Industry Insights - The licensing-out activity in the China healthcare industry is expected to remain robust in 2026, particularly in the area of immuno-oncology (IO) [2] - The transaction reflects overseas recognition of RemeGen's R&D capabilities and highlights the competitive landscape of the PD-(L)1/VEGF market, with other companies like Pfizer also advancing their products [2]

Core Insights - Junshi Bioscience reported a significant revenue increase of 49% year-on-year, reaching 1.168 billion yuan, while narrowing its net loss to 413 million yuan, a 36% reduction compared to the previous year [1] Revenue Performance - The sales revenue from pharmaceuticals reached 1.059 billion yuan, also reflecting a 49% year-on-year growth, driven primarily by the core product, Toripalimab [2] - Toripalimab's domestic sales amounted to 954 million yuan, marking a 42% increase, with 10 indications included in the national medical insurance directory [2] Global Expansion - Junshi Bioscience is accelerating the global rollout of Toripalimab, which has been approved in Australia, Singapore, UAE, and Kuwait, with applications submitted in 10 additional countries [3] - The company has established partnerships for commercialization, including a deal with LEO Pharma for European markets, involving an upfront payment of 15 million euros and a revenue-sharing agreement [3] R&D Focus - The company increased its R&D investment by 29% year-on-year to 706 million yuan, focusing on innovative IO 2.0 therapies [4] - Key pipelines include JS207, a PD-1/VEGF dual antibody currently in Phase II clinical trials, and JS213, a PD-1/IL-2 dual functional antibody fusion protein in Phase I trials [5] Future Pipeline - The first-in-class anti-BTLA monoclonal antibody, tifcemalimab, has entered Phase III clinical trials, while other candidates like Claudin18.2 ADC and PI3K-α inhibitors are expected to start Phase III trials in 2025 [6]

Group 1 - The Central Committee of the Communist Party of China emphasizes strengthening financial trial work and punishing financial crimes such as market manipulation and money laundering to promote healthy financial market development [2] - As of June 2025, the broad money supply (M2) in China reached 330.29 trillion yuan, growing by 8.3% year-on-year, while the narrow money supply (M1) was 113.95 trillion yuan, up by 4.6% [2] - The People's Bank of China (PBOC) has implemented a series of structural monetary policy tools to support technological innovation and consumption, with signed loan contracts for technological innovation reaching 1.74 trillion yuan by the end of May 2025 [3] Group 2 - In the first half of 2025, China's goods trade reached 21.79 trillion yuan, a year-on-year increase of 2.9%, with exports at 13 trillion yuan (up 7.2%) and imports at 8.79 trillion yuan (down 2.7%) [4] - The PBOC plans to conduct a 14 trillion yuan reverse repurchase operation to maintain liquidity in the banking system [3] - The State Council will hold a press conference on July 15, 2025, to discuss the national economic operation in the first half of 2025 [4] Group 3 - China Coal Transportation and Marketing Association emphasizes the need for coal enterprises to recognize the severe supply-demand imbalance and adhere to long-term contracts for electricity coal [6][7] - Dongguan City government promotes high-quality development of service consumption, focusing on digital consumption and technological innovation [7] - 招银国际 has received approval from the Hong Kong Securities and Futures Commission [8] Group 4 - 中盐化工 reported a 5.76% decrease in revenue for the first half of 2025, with net profit down 88.04% [8] - 金浦钛业 plans to exit the titanium dioxide industry through significant asset swaps [8] - 千方科技 expects a net profit increase of 1125.99% to 1534.65% for the first half of 2025 [10] Group 5 - 华宏科技 anticipates a net profit increase of 3047.48% to 3721.94% for the first half of 2025 [11] - 华夏航空 expects a net profit increase of 741.26% to 1008.93% for the first half of 2025 [12] - 高德红外 has signed a procurement agreement worth 879 million yuan for a complete equipment system [14] Group 6 - 星辉娱乐 plans to transfer 99.66% of its stake in the Spanish club for 130 million euros [15] - 中化装备 intends to acquire 100% of Yiyang Rubber Machinery and Beihua Machinery [16] - 特一药业 expects a net profit increase of 1164.22% to 1312.95% for the first half of 2025 [19] Group 7 - 航天科技 anticipates a net profit increase of 1628.83% to 2315.27% for the first half of 2025 [20] - 海立股份 expects a net profit increase of 625.83% to 756.71% for the first half of 2025 [21] - 恒生电子 projects a net profit increase of approximately 740.95% for the first half of 2025 [22] Group 8 - 杉杉股份 expects a net profit increase of 810.41% to 1265.61% for the first half of 2025 [23] - 国城矿业 anticipates a net profit increase of 1046.75% to 1174.69% for the first half of 2025 [24] - 游族网络 expects a net profit increase of 768.75% to 1203.13% for the first half of 2025 [25] Group 9 - 新易盛 anticipates a net profit increase of 327.68% to 385.47% for the first half of 2025 [26] - 万达电影 expects a net profit increase of 340.96% to 393.87% for the first half of 2025 [27] - 南都物业 projects a net profit increase of 387.02% to 630.52% for the first half of 2025 [27] Group 10 - 苏利股份 expects a net profit increase of 1008.39% to 1223.91% for the first half of 2025 [27] - 天齐锂业 anticipates a net profit of 0 to 155 million yuan, turning from loss to profit [27] - 华安证券 highlights the importance of IO 2.0 and breakthrough technology layouts in the pharmaceutical sector [29] Group 11 - 东海证券 notes strong performance in AI-related companies and suggests focusing on AIoT and consumer electronics sectors [30]

Core Viewpoint - The article highlights significant developments in China's financial and economic landscape, including regulatory measures, monetary policy updates, trade statistics, and corporate earnings forecasts. Group 1: Regulatory and Policy Developments - The Central Committee of the Communist Party of China emphasizes strengthening financial trial work to combat market manipulation, insider trading, illegal fundraising, loan fraud, and money laundering, while also improving rules for emerging financial disputes [2] - The People's Bank of China (PBOC) has implemented a series of structural monetary policy tools to support technology innovation and consumption, with a total loan contract amount for technology innovation reaching 1.74 trillion yuan by the end of May [3] - The PBOC plans to conduct a 14 billion yuan reverse repurchase operation to maintain liquidity in the banking system [4] Group 2: Economic Indicators - As of June 2025, the broad money supply (M2) in China reached 330.29 trillion yuan, growing by 8.3% year-on-year, while the narrow money supply (M1) was 113.95 trillion yuan, up by 4.6% [2] - In the first half of 2025, the total social financing increased by 22.83 trillion yuan, which is 4.74 trillion yuan more than the same period last year [2] - China's goods trade in the first half of 2025 totaled 21.79 trillion yuan, a year-on-year increase of 2.9%, with exports at 13 trillion yuan (up 7.2%) and imports at 8.79 trillion yuan (down 2.7%) [4] Group 3: Corporate Earnings and Developments - China National Salt Industry Corporation reported a 5.76% decrease in revenue for the first half of 2025, with net profit down 88.04% to 52.72 million yuan [8] - Jinpu Titanium Industry plans to exit the titanium dioxide industry through significant asset swaps [9] - Qianfang Technology expects a net profit increase of 1125.99% to 1534.65% for the first half of 2025 [10] - Huahong Technology anticipates a net profit increase of 3047.48% to 3721.94% for the same period [11] - Aerospace Science and Technology Corporation projects a net profit increase of 1628.83% to 2315.27% for the first half of 2025 [19]